Cellectar Biosciences, Inc. (CLRB) investor relations documents from the company's IR site: 4 presentations, 4 press releases; latest deck 2026-08-18. Read in-app with summaries. First-party data.
Corporate Presentation - August 2026 View Presentation: CELLECTAR BIOSCIENCES presents its PDC platform and pipeline, with iopofosine I 131 for WM in Phase 3, targeting FDA approval in 1H27.
| Published | Type | Document |
|---|---|---|
| 2026-08-18 | Presentation | Corporate Presentation - August 2026 View Presentation |
| 2026-08-13 | Press release | Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Read More |
| 2026-07-30 | Press release | Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 |
| 2026-07-21 | Presentation | Corporate Presentation - July 2026 |
| 2026-03-13 | Presentation | Corporate Presentation - March 2026 View Presentation |
| 2026-02-25 | Press release | Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 Learn |
| 2024-05-14 | Presentation | PresentationPDF |
| 2022-03-21 | Press release | Earnings ReleaseHTML |
CLRB overview · CLRB earnings · CLRB financials · CLRB KPIs · CLRB ownership · CLRB peers · CLRB filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.